Aurora Spine has been issued the second U.S. patent—entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use”—for its DEXA patient-matched implant technology.
 
DEXA technology was engineered to match the patient’s bone density and foster bone ingrowth while maintaining biomechanical structure and bone support. According to Aurora Spine, the new patent will be used to create implants that match the patient’s specific bone density, based on a DEXA scan/T-score to allow the most effective bone fusion treatment.
 
The company said DEXA was created and patented to combine the design benefits of conventional machining and additive implant manufacturing.
 
Aurora rolled out the first DEXA-based product, the DEXA-C interbody spacer line for anterior cervical fusion, in 2022. The company claims it is now well accepted by physicians as one of the most significant implant products to fight decreasing bone density due to aging.
 
The DEXA SOLO-L 3D-printed, standalone anterior lumbar interbody fusion (ALIF) implant earned U.S. Food and Drug Administration 510(k) clearance later in 2022.
 
Aurora Spine chief technology officer Laszlo Garamszegi said that traditionally, medical devices for spinal procedures are designed to be “one-size-fits-all” and assumes each patient’s bone density is the same.
 
“The proprietary engineering behind our DEXA Technology is advancing the science of implant technology, and ultimately helping improve patient fusion rates and overall clinical outcomes,” he said to the press. “These patents will allow us to create DEXA implants for use anywhere in the human body where bone fixation is needed providing patients with previously non-existing new treatment possibilities.”
 
“Aurora Spine’s first in the world and first to market DEXA Technology based implant provides surgeons with the choice in selecting the matching density implant for their patient,” said Aurora Spine president and CEO Trent Northcutt. “Aurora’s second patent for bone quality-matching implants strengthens the Company’s intellectual property portfolio significantly. Our proprietary DEXA Technology represents our continued commitment to delivering best-in-class implants that enable our surgeon partners to overcome common osteoporosis challenges faced in traditional procedures.”
 
In June 2023, Aurora Spine enrolled the first patient in its multicenter study of the DEXA-C cervical interbody system.